Response to: The paradox of implantable cardioverter-defibrillator: When guidelines play against care improvement - 18/02/21
Doi : 10.1016/j.ahj.2020.11.014
Godefroy S. Chery, MD, MHS a, ⁎, Nicholas Kamp, MD b, Andrzej S. Kosinski, PhD c, Gillian Sanders Schmidler, PhD c, d, Renato D. Lopes, MD, PhD d, Manesh Patel, MD d, Sana M. Al-Khatib, MD, MHS d
a Division of Cardiovascular Medicine, Department of Medicine, Hospital of the University of Pennsylvania, 2241 Sears Street, Philadelphia, PA, 19146
b Heart and Vascular Institute, Cleveland Clinic, Cleveland, OH
c Department of Biostatistics & Bioinformatics, Duke University School of Medicine, Durham, NC
d Division of Cardiology, Duke Clinical Research Institute, Duke University Medical Center, Durham, NC
⁎Reprint requests: Godefroy S. Chery, MD, MHS, Hospital of the University of Pennsylvania, Philadelphia, PA 19104.Hospital of the University of PennsylvaniaPhiladelphiaPA19104
Le texte complet de cet article est disponible en PDF.
Plan
© 2020
Publié par Elsevier Masson SAS.
Vol 233
P. 151-152 - mars 2021 Retour au numéro
Article précédent
- The paradox of implantable cardioverter-defibrillator: When guidelines may play against care improvement
- Marcello Disertori, Michela Masè, Marta Rigoni, Flavia Ravelli, Giandomenico Nollo
- Corrigendum to “Impact of creatinine clearance on clinical outcomes in elderly atrial fibrillation patients receiving apixaban: J-ELD AF Registry sub-analysis” [Am Heart J, 223 (2020), 23–33]
- Masaharu Akao, Takeshi Yamashita, Shinya Suzuki, Ken Okumura, J-ELD AF investigators
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?